158205-18-6

Basic information

• Product Name: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE
• Synonyms: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE;N-(6-BroMo-1-oxo-2,3-dihydro-1H-inden-5-yl)acetaMide
• CAS NO: 158205-18-6
• Molecular Formula: C₁₁H₁₀BrNO₂
• Molecular Weight: 268.11
• Mol File: 158205-18-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 162-164 °C
• Boiling Point: 458.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.631±0.06 g/cm3(Predicted)
• PKA: 13.60±0.20(Predicted)
• CAS DataBase Reference: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(158205-18-6)
• EPA Substance Registry System: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(158205-18-6)

Safety Data

• Hazardous Substances Data: 158205-18-6(Hazardous Substances Data)

Usage

General Description

N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE is a chemical compound with the molecular formula C12H11BrNO2. It is a yellow solid that is used in pharmaceutical research as a potential drug candidate. N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE is a derivative of acetamide containing a 6-bromo-2,3-dihydro-1-oxo-1H-inden-5-yl group, and its structure and properties make it a target for drug development. It may have potential applications in the treatment of various diseases and conditions, and further research is being conducted to explore its pharmacological properties and potential therapeutic uses.

Upstream product

• 157701-33-2 5-acetylamino-6-bromoindane 
• 59856-06-3 5-acetamidoindane 
• 24425-40-9 indan-5-amine 

Downstream Products

• 158205-19-7 5-Amino-6-bromo-1-indanone 
• 501169-57-9 tert-butyl 4-[N-(5-acetamido-6-bromoindan-1-yl)amino]benzoate 
• 851107-84-1 N-(6-bromo-4-nitro-1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 
• 851107-86-3 4,5-diamino-indan-1-one 
• 909555-35-7 7-benzyl-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-88-5 7-(4-fluoro-benzylidene)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-89-6 7-(4-fluorobenzyl)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 501170-72-5 5-benzyloxyacetamido-6-bromoindan-1-one 
• 501170-90-7 tert-butyl 4-{N-[2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]amino}benzoate 
• 501170-76-9 tert-butyl 4-[N-(5-(2-benzyloxy-ethanoylamino)-6-bromoindan-1-yl)amino]benzoate 
• 501132-07-6 tert-butyl 4-{N-[2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoate 
• 501170-80-5 tert-butyl 4-[N-(5-(2-benzyloxy-ethanoylamino)-6-cyanoindan-1-yl)amino]benzoate 
• 501170-85-0 tert-butyl 4-{N-[2-benzyloxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]amino}benzoate 
• 174487-71-9 4-{N-[(6R/6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid 

Relevant articles and documents

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity

IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Antifolate chemistry: Synthesis of 4-{N-[(6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid via a (propargyl)Co2(CO)6+ complex

A new route to compound 3 (4-{N-[(6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid), a crucial intermediate for the synthesis of potent inhibitors of thymidylate synthase (TS), is described. In this sequence the C6-N10 bond was constructed first, by the reductive amination of 5-acetamido-6-bromoindan-1-one 6 with tert-butyl 4-aminobenzoate, then the cyclopenta[g]quinazolinone ring was formed and the propargyl group was introduced on the N10-position using the (propargyl)Co2(CO)6+ complex as the electrophilic propargyl reagent.